Analysts Set Medpace Holdings, Inc. (NASDAQ:MEDP) Price Target at $422.27

Key Points

• Medpace Holdings, Inc. has received a consensus rating of "Reduce" from 16 research firms, with three analysts recommending a sell, eleven a hold, and two a buy.
• The average 1-year price target for Medpace is reported to be $422.27, despite recent price target adjustments by various analysts upwards to $490.00.
• Medpace's recent quarterly earnings showed a profit of $3.10 EPS, exceeding expectations, alongside a 14.2% revenue increase year-over-year.

Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) has earned a consensus rating of "Reduce" from the sixteen brokerages that are covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, eleven have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $422.2727.

Several equities research analysts have issued reports on MEDP shares. Mizuho lifted their target price on shares of Medpace from $328.00 to $510.00 and gave the stock an "outperform" rating in a research note on Friday, July 25th. TD Cowen restated a "sell" rating and set a $366.00 target price (up from $283.00) on shares of Medpace in a report on Wednesday, July 23rd. William Blair reissued a "market perform" rating on shares of Medpace in a research note on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft raised their target price on Medpace from $270.00 to $430.00 and gave the stock a "hold" rating in a research note on Wednesday, July 23rd. Finally, UBS Group cut shares of Medpace from a "neutral" rating to a "sell" rating and boosted their price target for the company from $300.00 to $305.00 in a research report on Tuesday, July 29th.

Medpace Stock Performance

Medpace stock traded down $0.52 during trading on Friday, reaching $498.08. The company had a trading volume of 155,854 shares, compared to its average volume of 316,492. The firm has a market capitalization of $13.99 billion, a PE ratio of 37.03, a price-to-earnings-growth ratio of 3.14 and a beta of 1.44. The firm's 50-day simple moving average is $450.44 and its 200 day simple moving average is $356.61. Medpace has a 1-year low of $250.05 and a 1-year high of $506.55.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its earnings results on Monday, July 21st. The company reported $3.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.00 by $0.10. The business had revenue of $603.31 million for the quarter, compared to analyst estimates of $537.70 million. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The company's revenue for the quarter was up 14.2% compared to the same quarter last year. During the same quarter last year, the business earned $2.75 earnings per share. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. Analysts anticipate that Medpace will post 12.29 EPS for the current year.

Insider Transactions at Medpace

In other Medpace news, President Jesse J. Geiger sold 41,801 shares of the stock in a transaction that occurred on Thursday, July 24th. The shares were sold at an average price of $453.11, for a total transaction of $18,940,451.11. Following the sale, the president directly owned 36,503 shares in the company, valued at $16,539,874.33. This represents a 53.38% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Susan E. Burwig sold 10,000 shares of the company's stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $480.00, for a total value of $4,800,000.00. Following the sale, the vice president directly owned 57,500 shares in the company, valued at $27,600,000. This represents a 14.81% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 161,266 shares of company stock valued at $74,111,427. 20.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Medpace

Several hedge funds have recently made changes to their positions in the business. Quantinno Capital Management LP boosted its holdings in shares of Medpace by 43.0% in the fourth quarter. Quantinno Capital Management LP now owns 1,148 shares of the company's stock valued at $381,000 after acquiring an additional 345 shares in the last quarter. Royal Bank of Canada raised its position in Medpace by 1.9% in the fourth quarter. Royal Bank of Canada now owns 48,398 shares of the company's stock worth $16,078,000 after acquiring an additional 890 shares in the last quarter. Snowden Capital Advisors LLC acquired a new stake in Medpace in the fourth quarter valued at $222,000. Vident Advisory LLC boosted its position in shares of Medpace by 9.6% during the 4th quarter. Vident Advisory LLC now owns 4,716 shares of the company's stock worth $1,567,000 after purchasing an additional 412 shares in the last quarter. Finally, Woodline Partners LP purchased a new position in shares of Medpace in the 4th quarter valued at about $5,305,000. Institutional investors and hedge funds own 77.98% of the company's stock.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.